Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more
Amplia Therapeutics Limited (INNMF) - Total Assets
Latest total assets as of September 2025: $44.54 Million USD
Based on the latest financial reports, Amplia Therapeutics Limited (INNMF) holds total assets worth $44.54 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Amplia Therapeutics Limited - Total Assets Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Amplia Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Amplia Therapeutics Limited's total assets of $44.54 Million consist of 65.1% current assets and 34.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 47.4% |
| Accounts Receivable | $3.77 Million | 16.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.94 Million | 34.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2025)
This chart illustrates how Amplia Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amplia Therapeutics Limited's current assets represent 65.1% of total assets in 2025, an increase from 14.1% in 2010.
- Cash Position: Cash and equivalents constituted 47.4% of total assets in 2025, up from 13.5% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, a decrease from 82.0% in 2010.
- Asset Diversification: The largest asset category is intangible assets at 34.6% of total assets.
Amplia Therapeutics Limited Competitors by Total Assets
Key competitors of Amplia Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Amplia Therapeutics Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Amplia Therapeutics Limited generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Amplia Therapeutics Limited is currently not profitable relative to its asset base.
Amplia Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.18 | 4.35 | 7.60 |
| Quick Ratio | 28.18 | 4.35 | 7.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $34.81 Million | $ 4.74 Million | $ 4.06 Million |
Amplia Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Amplia Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.61 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 54.5% |
| Total Assets | $22.94 Million |
| Market Capitalization | $20.60 Million USD |
Valuation Analysis
Near Book Valuation: The market values Amplia Therapeutics Limited's assets close to their book value ( 0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Amplia Therapeutics Limited's assets grew by 54.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Amplia Therapeutics Limited (2010–2025)
The table below shows the annual total assets of Amplia Therapeutics Limited from 2010 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $22.94 Million | +54.51% |
| 2024-03-31 | $14.85 Million | -20.55% |
| 2023-03-31 | $18.68 Million | -23.69% |
| 2022-03-31 | $24.48 Million | +125.05% |
| 2021-03-31 | $10.88 Million | +19.34% |
| 2020-03-31 | $9.12 Million | -0.82% |
| 2019-03-31 | $9.19 Million | +247.67% |
| 2018-03-31 | $2.64 Million | -64.92% |
| 2017-03-31 | $7.54 Million | +49.70% |
| 2016-03-31 | $5.03 Million | -5.35% |
| 2015-03-31 | $5.32 Million | -47.73% |
| 2014-03-31 | $10.18 Million | -10.94% |
| 2013-03-31 | $11.43 Million | +98.92% |
| 2012-03-31 | $5.74 Million | -26.86% |
| 2011-03-31 | $7.85 Million | -4.31% |
| 2010-03-31 | $8.21 Million | -- |